[CAS NO. 1381930-17-1] TBK1/IKKε-IN-4
PRODUCTS SPECIFICATIONS [1381930-17-1]
DESCRIPTION [1381930-17-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 533.62 |
| Molecular Formula | C28H35N7O4 |
| SMILES | COC1=CC=C(N2N=CC3=CN=C(NC4=CC(OCCCN5CCN(C)CC5)=C(OC)C(OC)=C4)N=C32)C=C1 |
Summary
IC50 & Target
|
IKKε 59 nM (IC 50 ) |
TBK1 13 nM (IC 50 ) |
In Vitro
TBK1/IKKε-IN-4 (Compound II; 96 hours; A549 andHCC44 cells) treatmentdisplays selective toxicity in TBK1-dependent cancer cell lines (IC
50
of ~ 4.2 µM for H441 cells and IC
50
of ~0.4 µM for A549 cells)
[1]
.
TBK1/IKKε-IN-4 (Compound II; 0-2 µM; 30 minutes; HCC44 cells) treatment inhibits the AKT activity
[1]
.
TBK1/IKKε-IN-4 (Compound II) inhibits LPS-induced expression of IFNβ (IC
50
=62 nM), and the IFNβ target genes IP10 (IC
50
=78 nM) and Mx1 (IC
50
=20 nM). TBK1/IKKε-IN-4 effectively blocksTLR3-dependent IRF3 nuclear translocation in cells with an IC
50
under 100 nM, but does not impair TNFR1-dependent p65 NFκB nuclear translocation with doses as high as 20 µM
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | HCC44 cells |
| Concentration: | 0 µM, 0.5 µM, 1 µM, 2 µM |
| Incubation Time: | 30 minutes |
| Result: | Was sufficient to blunt baseline AKT activity. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 70 mg/mL ( 131.18 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.8740 mL | 9.3700 mL | 18.7399 mL |
| 5 mM | 0.3748 mL | 1.8740 mL | 3.7480 mL |
| 10 mM | 0.1874 mL | 0.9370 mL | 1.8740 mL |
